Clinical trials for Acute leukemia
61 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Early Access
Acute leukemia
Required histologic types
Acute lymphoblastic leukemia (ALL)
Required histologic sub types
B-cell (B-ALL)
Required immunophenotypic profiles
CD19
Required number of previous lines of therapy
None
Required previous treatments
Chemotherapy
Excluded genetic anomalies
Ph+ (Philadelphia chromosome positive)
Excluded previous treatments
Systemic Treatment-Naive
1 recruiting site
Amgen
Early Access
Acute leukemia
Required histologic types
Acute lymphoblastic leukemia (ALL)
Required histologic sub types
B-cell (B-ALL)
Required immunophenotypic profiles
CD19
Required number of previous lines of therapy
None
Required previous treatments
Chemotherapy
Excluded genetic anomalies
Ph+ (Philadelphia chromosome positive)
Excluded previous treatments
Systemic Treatment-Naive
1 recruiting site
Amgen
Phase 3
Acute leukemia
#NCT07007312
#2025-521314-25-00
Etude de thérapie intensive
Required histologic types
Acute myeloid leukemia (AML)
Required genetic anomalies
KMT2A
NPM1
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded genetic anomalies
BCR-ABL
8 recruiting sites
Kura Oncologie, Inc.
Phase 3
Acute leukemia
#NCT07007312
#2025-521314-25-00
Etude de thérapie non intensive
Required histologic types
Acute myeloid leukemia (AML)
Required genetic anomalies
NPM1
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded genetic anomalies
BCR-ABL
8 recruiting sites
Kura Oncologie, Inc.
Phase 3
Acute leukemia
#NCT04307576
#2022-501050-11-01
Required histologic types
Acute lymphoblastic leukemia (ALL)
Required histologic sub types
T-cell (T-ALL)
B-cell (B-ALL)
Required genetic anomalies
MYC
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
28 recruiting sites
Karolinska University Hospital
Phase 3
Acute leukemia
#NCT03655145
Required histologic types
Acute lymphoblastic leukemia (ALL)
Acute myeloid leukemia (AML)
Required number of previous lines of therapy
None
Required previous treatments
Chemotherapy
1 recruiting site
Assistance Publique - Hôpitaux de Paris
Phase 3
Acute leukemia
#NCT05429632
#2024-512752-38-00
Required histologic types
Acute myeloid leukemia (AML)
Required number of previous lines of therapy
None
4 recruiting sites
Priothera SAS
Phase 3
Acute leukemia
#NCT06852222
#2024-520154-38-00
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None
Treated / Controled
Required genetic anomalies
KMT2A
NPM1
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
13 recruiting sites
Janssen
Phase 3
Acute leukemia
#NCT05907057
#2022-501709-11
Required histologic types
Acute myeloid leukemia (AML)
Required genetic anomalies
IDH1/2
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Chemotherapy
3 recruiting sites
Servier
Phase 3
Acute leukemia
#NCT06578247
#2023-507936-20-00
Required histologic types
Acute myeloid leukemia (AML)
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded genetic anomalies
FLT3-ITD
BCR-ABL
Excluded previous treatments
Chemotherapy
15 recruiting sites
Daiichi Sankyo